Jenburkt Pharmaceuticals (BOM:524731) E10: ₹58.88 (As of Mar. 2026)


BOM:524731 Jenburkt Pharmaceuticals Ltd BOM:524731
82 GF Score
Price ₹1,114.65
GF Value ₹1,114.52
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Jenburkt Pharmaceuticals E10?

Jenburkt Pharmaceuticals BOM:524731 +1.21% 82 E10 is ₹58.88 as of Mar. 2026. GuruFocus rates BOM:524731 with a GF Score™ of 82/100 and a GF Value™ of ₹1,114.52 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Jenburkt Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was ₹24.580. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹58.88 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Jenburkt Pharmaceuticals's average E10 Growth Rate was 12.30% per year. During the past 3 years, the average E10 Growth Rate was 11.70% per year. During the past 5 years, the average E10 Growth Rate was 12.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Jenburkt Pharmaceuticals was 12.50% per year. The lowest was 11.70% per year. And the median was 12.30% per year.

As of today (2026-07-12), Jenburkt Pharmaceuticals's current stock price is ₹1114.65. Jenburkt Pharmaceuticals's E10 for the quarter that ended in Mar. 2026 was ₹58.88. Jenburkt Pharmaceuticals's Shiller PE Ratio of today is 18.93.

During the past 13 years, the highest Shiller PE Ratio of Jenburkt Pharmaceuticals was 25.75. The lowest was 11.16. And the median was 16.18.


Jenburkt Pharmaceuticals  (BOM:524731) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Jenburkt Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=1114.65/58.88
=18.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Jenburkt Pharmaceuticals was 25.75. The lowest was 11.16. And the median was 16.18.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Jenburkt Pharmaceuticals E10 Related Terms


Jenburkt Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Jenburkt Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jenburkt Pharmaceuticals E10 Chart

Jenburkt Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.04 42.29 47.27 52.43 58.88

Jenburkt Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.43 54.05 56.03 56.53 58.88

BOM:524731 vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jenburkt Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jenburkt Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jenburkt Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Jenburkt Pharmaceuticals's Shiller PE Ratio falls into.


BOM:524731
82GF Score
Jenburkt Pharmaceuticals Ltd BOM:524731
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jenburkt Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jenburkt Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=24.58/164.2724*164.2724
=24.580

Current CPI (Mar. 2026) = 164.2724.

Jenburkt Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201606 4.190 105.961 6.496
201609 10.884 105.961 16.874
201612 6.350 105.196 9.916
201703 7.600 105.196 11.868
201706 -6.190 107.109 -9.494
201709 21.450 109.021 32.321
201712 9.890 109.404 14.850
201803 12.150 109.786 18.180
201806 5.880 111.317 8.677
201809 12.520 115.142 17.862
201812 9.720 115.142 13.867
201903 15.020 118.202 20.874
201906 0.130 120.880 0.177
201909 12.100 123.175 16.137
201912 10.110 126.235 13.156
202003 10.060 124.705 13.252
202006 2.200 127.000 2.846
202009 12.360 130.118 15.604
202012 12.960 130.889 16.265
202103 8.450 131.771 10.534
202106 10.130 134.084 12.411
202109 17.370 135.847 21.005
202112 13.570 138.161 16.135
202203 7.510 138.822 8.887
202206 12.970 142.347 14.968
202209 14.960 144.661 16.988
202212 11.840 145.763 13.343
202303 14.130 146.865 15.805
202306 12.170 150.280 13.303
202309 16.590 151.492 17.990
202312 12.250 152.924 13.159
202403 17.860 153.035 19.172
202406 16.800 155.789 17.715
202409 21.750 157.882 22.630
202412 14.750 158.323 15.304
202503 19.340 157.552 20.165
202506 17.660 159.755 18.159
202509 23.030 162.289 23.311
202512 13.440 163.281 13.522
202603 24.580 164.272 24.580

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹58.88 mean?
Jenburkt Pharmaceuticals (BOM:524731) has a E10 of ₹58.88 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Jenburkt Pharmaceuticals and its competitors.
Is Jenburkt Pharmaceuticals' E10 too high?
Jenburkt Pharmaceuticals' current E10 is ₹58.88. Overall, Jenburkt Pharmaceuticals has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jenburkt Pharmaceuticals' E10 compare to ZTS and UTHR?
Jenburkt Pharmaceuticals' E10 of ₹58.88 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Jenburkt Pharmaceuticals and its competitors. Jenburkt Pharmaceuticals's current E10 is ₹58.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jenburkt Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Jenburkt Pharmaceuticals (BOM:524731) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,114.52, compared to a current price of ₹1,114.65 — trading 0% above its estimated fair value. The current E10 is ₹58.88. Jenburkt Pharmaceuticals' overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Jenburkt Pharmaceuticals (BOM:524731), the current E10 is ₹58.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jenburkt Pharmaceuticals (BOM:524731) Overvalued in 2026?

Based on GuruFocus' analysis, Jenburkt Pharmaceuticals stock appears to be overvalued. The current stock price of ₹1,114.65 is trading 0% above its estimated GF Value™ of ₹1,114.52. GuruFocus considers Jenburkt Pharmaceuticals to be Fairly Valued.

Key valuation signals for BOM:524731:

  • E10: ₹58.88
  • GF Value™: ₹1,114.52 vs. price of ₹1,114.65 (0% above fair value)
  • GF Score™: 82/100 with 1 warning sign

No single metric tells the full story. See the BOM:524731 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jenburkt Pharmaceuticals Business Description

Address 93, Jayprakash Road, Nirmala Apartments, Andheri (West, Mumbai, MH, IND, 400058
Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, producing, developing, and marketing of pharmaceutical formulations. The company operates in one segment - pharmaceutical formulations. The company generates key revenue from the local market.
82GF Score

Get the complete analysis for BOM:524731

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,114.65
Price
₹1,114.52
GF Value